Table TDI-12. Characteristics of all women treated for drug problems in 2002 or most recent year available. Part (ii) Distribution of primary drug (percentage)

Country		Opiates	Cocaine	Amphetamines	Ecstasy	Hallucinogens	Cannabis	Others

Belgium	⁽¹⁾	61	2	5	2	0	15	15
Czech Republic	⁽²⁾	25.6	0.1	53.3	2.6	0.2	13.8	4.4
Denmark	⁽³⁾	46	2	5	2	0	23	22
Germany	⁽⁴⁾	54	4	9	na	0	22	11
Greece		88.5	2.5	0	0.8	0	5.5	2.7
Spain	⁽¹⁷⁾	64	22	1	1	0	7	5
France	⁽⁵⁾	78.6	4	0.5	0.4	0.2	10.1	6.2
Ireland	⁽⁶⁾	77.2	0.6	0.4	4.6	0.1	13.1	4
Italy	⁽⁷⁾	na	na	na	na	na	na	na
Latvia	⁽⁸⁾	80.2	0	10.7	na	0.2	0.2	8.7
Lithuania	⁽⁹⁾	na	na	na	na	na	na	na
Luxembourg		79	9	0	0	0	8	4
Hungary	⁽¹¹⁾	na	na	na	na	na	na	na
Netherlands	⁽¹²⁾	40	32	3	1	0	17	7
Austria	⁽¹³⁾	100
Slovenia		86	1.2	0.2	0.7	0	10.5	1.4
Slovakia		78.9	0.2	5.4	0.2	0	5.8	9.5
Finland		33.2	0	39.9	0.9	0	15.8	10.2
Sweden	⁽¹⁵⁾	28	1	29	1	0	18	23
United Kingdom	⁽¹⁶⁾	77	6	4	1	0	7	5

Notes:
		Data were not available for: Estonia, Cyprus, Malta, Poland and Norway.
		Injecting as a route of administration is not reported for cannabis.
Belgium	⁽¹⁾	Data refer only to outpatient treatment centres. Last data available refer to 1999
Czech Republic	⁽²⁾	Data refer to all treatment centres.
Denmark	⁽³⁾	Injecting use for opiates refers only to heroin, and cocaine only to cocaine CIH. For distribution by main drug only clients attending outpatient centres.
Germany	⁽⁴⁾	Data only refer to outpatient treatment centres; information about injecting use is not available. Amphetamines also include ecstasy.
France	⁽⁵⁾	The last available data on treatment demand are reported, referring to the annual census on clients in treatment carried out in November 1999.
Ireland	⁽⁶⁾	Last data available refer to 2000.
Italy	⁽⁷⁾	Data only refer to outpatient treatment centres; information about injecting opiate use refers only to heroin, for cocaine only to cocaine CIH.
Latvia	⁽⁸⁾	Data refer only to outpatient treatment centres.
Lithuania	⁽⁹⁾	Amphetamines include all stimulants.
Hungary	⁽¹¹⁾	39% of clients are reported to use hypnotics/sedatives, 18% other substances.
Netherlands	⁽¹²⁾	Data refer only to outpatient treatment centres.
Austria	⁽¹³⁾	Data refer to clients in substitution treatment only; figures for opiates as main drug and injecting use are consequently 100%.
Portugal	⁽¹⁴⁾	Coverage is limited and variable, with no control on double counting of clients.
Sweden	⁽¹⁵⁾	Data refer only to outpatient treatment centres.
United Kingdom	⁽¹⁶⁾	Data relate to the period from 1 April 2001 to 31 March 2002 for Scotland and Northern Ireland; for England and Wales six months data ending 30 September 2000 plus six months data ending 31 March 2001.
Spain	⁽¹⁷⁾	Data on men and women only concern outpatient treatment centres.

Sources: 2003 Reitox national reports, Standard table, 3 see [Table TDI-10 Part (iii)] for details on sources.

Download